This page collects WhisperX intelligence signals tagged #Immunology. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
Biogen is making a massive $5.6 billion bet on immunology, announcing a deal to acquire Apellis Pharmaceuticals at a price more than double the biotech's recent share value. The upfront cash offer of $41 per share represents a dramatic premium, signaling Biogen's aggressive push to secure commercial-stage assets and re...
Biogen has made a decisive $5.6 billion move to acquire Apellis Pharmaceuticals, marking one of its largest-ever acquisitions. The deal is a strategic pivot to significantly expand Biogen's portfolio in immunology and rare disease treatments, signaling a major investment in a high-value therapeutic area. This acquisiti...
Sanofi's investigational drug lunsekimig has successfully met both its primary and key secondary endpoints in two separate Phase 2 clinical trials, signaling a significant step forward for the biopharma giant's pipeline. The trials evaluated the drug's efficacy and safety in treating patients with asthma and chronic rh...
Five years ago, a single, desperate case in Germany shattered a core assumption in immunology. Georg Schett, a physician-scientist, faced a young lupus patient near death and a radical idea: using engineered CAR-T cells, a cancer therapy, to treat an autoimmune disease. The prevailing fear was that these powerful T cel...